Medication info
Acyclovir Tablet (Acyclovir)

Acyclovir Tablet (Acyclovir)

Prescription medicationTabletIntravenous injection
Ingredient · strength
Acyclovir›200mg / 1 tablet
Manufacturer / importer
Intro Biopharma Co., Ltd.
Appearance
Light blue round tablet
Packaging
30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201803531 · Approved 2018.08.29 · Insurance code 052400830

Summary

Main use
Treatment of herpes zoster; treatment and prevention of herpes simplex; treatment of chickenpox in children
Who receives it
Adults · Children
Adult administration
1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. In severe initial infections, treatment may be extended. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Treatment should be started as soon as possible after infection; in recurrent cases, it is preferable to start treatment at the onset of prodromal symptoms or when lesions first appear. 2. Prevention of herpes simplex infections in immunocompetent patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) Thereafter, the dose may be reduced to 200 mg per dose 2~3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically discontinued every 6~12 months for evaluation. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg per dose 5 times daily at approximately 4-hour intervals, omitting bedtime, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunocompromise or gastrointestinal malabsorption. 3) Treatment should be started as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more susceptible to neuropsychiatric adverse reactions; therefore, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is preferable to administer 200 mg every 12 hours. 2. Treatment of varicella-zoster virus infections 1) In patients with creatinine clearance less than 10 mL per minute, it is preferable to reduce the dose to 800 mg per administration twice daily, at approximately 12-hour intervals. 2) In patients with creatinine clearance of 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg per administration 3 times daily, at approximately 8-hour intervals.
Child administration
1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients Age 2 years and older: Same as adults. Under 2 years: Administer 1/2 the adult dose. There are currently no reliable data on prevention of herpes simplex virus infections in immunocompetent patients. 2. Treatment of chickenpox in children aged 2 years and older Children aged 2 years and older: Administer 20 mg/kg body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment is most effective when started as soon as possible after the chickenpox rash appears, preferably within 24 hours of rash onset.

Ingredients

Manufacturer
Intro Biopharma Co., Ltd.

Efficacy & effects

Treatment of herpes zoster; treatment and prevention of herpes simplex; treatment of chickenpox in children

  • Primary genital herpes
  • recurrent genital herpes
  • herpes simplex virus infections of the skin
  • herpes simplex virus infections of mucous membranes
  • shingles virus infections
  • acute herpes zoster pain
  • chickenpox.
View approved original text

This medication is used for the treatment and prevention of herpes simplex virus infections in skin and mucous membrane tissues, including primary and recurrent genital herpes. Additionally, it is effective in treating shingles virus infections, particularly helping relieve acute pain. However, its efficacy for postherpetic neuralgia is not yet proven. This medication is also used to treat chickenpox in children aged 2 years and older. Overall, it is a drug that helps in the treatment and prevention of various viral infections.

How it is given

Adult administration

1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. In severe initial infections, treatment may be extended. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Treatment should be started as soon as possible after infection; in recurrent cases, it is preferable to start treatment at the onset of prodromal symptoms or when lesions first appear. 2. Prevention of herpes simplex infections in immunocompetent patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) Thereafter, the dose may be reduced to 200 mg per dose 2~3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically discontinued every 6~12 months for evaluation. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg per dose 5 times daily at approximately 4-hour intervals, omitting bedtime, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunocompromise or gastrointestinal malabsorption. 3) Treatment should be started as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more susceptible to neuropsychiatric adverse reactions; therefore, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is preferable to administer 200 mg every 12 hours. 2. Treatment of varicella-zoster virus infections 1) In patients with creatinine clearance less than 10 mL per minute, it is preferable to reduce the dose to 800 mg per administration twice daily, at approximately 12-hour intervals. 2) In patients with creatinine clearance of 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg per administration 3 times daily, at approximately 8-hour intervals.

Child administration

1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients Age 2 years and older: Same as adults. Under 2 years: Administer 1/2 the adult dose. There are currently no reliable data on prevention of herpes simplex virus infections in immunocompetent patients. 2. Treatment of chickenpox in children aged 2 years and older Children aged 2 years and older: Administer 20 mg/kg body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment is most effective when started as soon as possible after the chickenpox rash appears, preferably within 24 hours of rash onset.

Precautions

This medication should not be used by individuals allergic to this medication, its components, or valacyclovir. Patients with impaired kidney function may experience psychiatric and neurological side effects more easily, so caution is advised. Patients with decreased liver function should be administered this medication carefully because of the risk of worsening liver function. In infants and children, it should be used minimally and only when necessary, especially in newborns or low-birth-weight infants, weighing the risks and benefits carefully. Elderly patients may have diminished kidney function, leading to increased concentrations of this medication and more frequent side effects; dosage and intervals should be adjusted carefully. Rarely, anaphylaxis, a severe allergic reaction, may occur; if symptoms of low blood pressure, shortness of breath, or chest tightness arise, administration should be discontinued immediately, and appropriate treatment should be sought. If skin hypersensitivity reactions, rash, fever, blisters, or hives appear, use of this medication should be stopped and a physician should be consulted. Alopecia, various skin rashes, and serious skin disorders (Stevens-Johnson syndrome, toxic epidermal necrolysis) may also occur, so caution is advised. It may affect the mental state or neurological system, leading to consciousness disorders, disorientation, decreased concentration, aggressive behavior, hallucinations, seizures, drowsiness, insomnia, anxiety, and various other symptoms, particularly more frequently in elderly patients or patients with decreased kidney function. It can lead to kidney issues resulting in symptoms like kidney failure, hematuria, or proteinuria, hence periodic monitoring of kidney function is required. It may also affect the blood and lymphatic system, resulting in changes in blood cell counts, bleeding, or anemia. Liver function abnormalities, hepatitis, or jaundice may occur; regular liver function tests are recommended. Gastrointestinal symptoms such as gastritis, constipation, diarrhea, vomiting, or abdominal pain might occur; if symptoms are severe, use should be stopped. Systemically, fever, swelling, weakness, or headache may also manifest. Muscle pain or joint pain may occur; if there are unusual symptoms, consulting a physician is necessary. It can also affect the heart and blood pressure, leading to arrhythmias, chest pain, or fluctuations in blood pressure. Urination issues or urination obstruction symptoms may rarely occur; any urine abnormalities should be reported. When using this medication, if symptoms do not improve or worsen, other treatment options should be considered; particularly, for shingles and chickenpox, starting treatment as early as possible after the onset of skin symptoms is crucial. In patients with compromised immunity, intravenous options may be considered. Adequate hydration is required during treatment with this medication to reduce the risk of renal toxicity from dehydration. Patients with recurrent genital herpes should consult their physician about whether to continue treatment after one year. Consciousness disorders may occur during treatment, hence caution is advised when driving or operating hazardous machinery. There may be interactions with other medications; especially when taken with probenecid, cimetidine, theophylline, mycophenolate mofetil, etc., consult a physician or pharmacist. Women who are pregnant or may become pregnant should use this medication cautiously, considering the potential risks; during breastfeeding, since this medication may transfer to breast milk, it is advisable to discontinue breastfeeding.

Side effects

  • Anaphylactic shock
  • anaphylactic reaction
  • hypotension
  • dyspnea
  • chest tightness
  • photosensitivity reaction
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 118 more
  • urticarial erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • disorientation
  • concentration impairment
  • aggressive behavior
  • depersonalization
  • agitation
  • ataxia
  • coma
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucinations
  • psychosis
  • convulsions
  • drowsiness
  • tremors
  • excitement
  • forgetfulness
  • insomnia
  • anxiety
  • talking to oneself
  • abnormal sensations
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • dizziness
  • renal failure
  • crystalluria
  • elevated BUN
  • elevated serum creatinine
  • hematuria
  • proteinuria
  • urinary red blood cell casts
  • pyuria
  • leukocytoclastic vasculitis
  • lymphadenopathy
  • bleeding
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • loose stools
  • upper abdominal pain
  • gastric pain
  • abdominal pain
  • nausea
  • vomiting
  • dyspepsia
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • fatigue
  • generalized malaise
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • hypertension
  • hypotension
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glycosuria
  • pneumonia
  • pharyngitis
  • pleural effusion
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • alopecia
  • sweating
  • hyponatremia
  • decreased serum protein
  • elevated total cholesterol level
  • elevated triglyceride level
  • elevated serum potassium level
  • decreased serum albumin level
  • agitation
  • coma
  • convulsions
  • drowsiness
  • confusion
  • hallucinations
  • excitement
  • seizure
  • comatose state

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the efficacy of the medication and prevents deterioration.

Appearance and packaging

Appearance

Light blue round tablet

Package unit

30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.